Vasculitis update, 2007.
Vasculitic syndromes are among the most complicated diseases to treat and manage. New medications and new ways of using old medications have provided us with new therapies to treat our patients. This review focuses on recent date that may have an impact on the way vasculitis is treated.
Yazici
Yusuf
Y
New York University School of Medicine, and Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA. Yusuf.yazici@nyumc.org
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D013700:Giant Cell Arteritis / Q000188:drug therapy*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D018501:Antirheumatic Agents; D003520:Cyclophosphamide; D001241:Aspirin; D008727:Methotrexate